1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
LYS 2 - GLY 3 MODEL 1 OMEGA = 148.91 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
GLY 3 - LYS 4 MODEL 1 OMEGA = 210.78 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
LYS 25 - CYS 26 MODEL 1 OMEGA = 210.64 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
CYS 1 - LYS 2 MODEL 2 OMEGA = 210.60 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
ARG 9 - LYS 10 MODEL 2 OMEGA = 210.11 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
CYS 16 - SER 17 MODEL 2 OMEGA = 210.32 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
GLY 18 - SER 19 MODEL 2 OMEGA = 210.06 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
LYS 4 - GLY 5 MODEL 3 OMEGA = 210.33 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
ARG 9 - LYS 10 MODEL 3 OMEGA = 210.47 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
MET 12 - TYR 13 MODEL 3 OMEGA = 149.80 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
CYS 16 - SER 17 MODEL 3 OMEGA = 210.90 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
GLY 18 - SER 19 MODEL 3 OMEGA = 210.74 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
LYS 2 - GLY 3 MODEL 4 OMEGA = 149.39 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
GLY 3 - LYS 4 MODEL 4 OMEGA = 210.17 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
LYS 25 - CYS 26 MODEL 4 OMEGA = 210.88 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
GLY 3 - LYS 4 MODEL 5 OMEGA = 210.46 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
ARG 9 - LYS 10 MODEL 5 OMEGA = 210.13 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
GLY 18 - SER 19 MODEL 5 OMEGA = 210.07 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
LYS 25 - CYS 26 MODEL 5 OMEGA = 211.17 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
LYS 2 - GLY 3 MODEL 6 OMEGA = 149.18 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
CYS 1 - LYS 2 MODEL 7 OMEGA = 210.47 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
LYS 2 - GLY 3 MODEL 7 OMEGA = 148.72 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
GLY 3 - LYS 4 MODEL 7 OMEGA = 210.60 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
ARG 9 - LYS 10 MODEL 7 OMEGA = 210.28 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
CYS 16 - SER 17 MODEL 7 OMEGA = 210.33 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
LYS 25 - CYS 26 MODEL 7 OMEGA = 211.16 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
LYS 2 - GLY 3 MODEL 8 OMEGA = 149.60 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
CYS 16 - SER 17 MODEL 8 OMEGA = 210.08 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
ARG 9 - LYS 10 MODEL 9 OMEGA = 210.31 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
CYS 16 - SER 17 MODEL 9 OMEGA = 210.41 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
CYS 1 - LYS 2 MODEL 10 OMEGA = 210.21 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
LYS 2 - GLY 3 MODEL 10 OMEGA = 148.67 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
GLY 3 - LYS 4 MODEL 10 OMEGA = 210.30 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
ARG 9 - LYS 10 MODEL 10 OMEGA = 210.46 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
CYS 20 - GLY 21 MODEL 10 OMEGA = 210.21 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
LYS 25 - CYS 26 MODEL 10 OMEGA = 210.35 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
LYS 2 - GLY 3 MODEL 11 OMEGA = 149.99 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
SER 17 - GLY 18 MODEL 11 OMEGA = 210.04 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
ARG 9 - LYS 10 MODEL 12 OMEGA = 210.13 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
LYS 25 - CYS 26 MODEL 12 OMEGA = 211.32 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
LYS 2 - GLY 3 MODEL 13 OMEGA = 149.83 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
GLY 3 - LYS 4 MODEL 13 OMEGA = 210.39 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
ARG 9 - LYS 10 MODEL 13 OMEGA = 210.20 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
LYS 25 - CYS 26 MODEL 13 OMEGA = 210.60 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
ARG 9 - LYS 10 MODEL 14 OMEGA = 210.52 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
ASP 14 - CYS 15 MODEL 14 OMEGA = 210.33 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
CYS 16 - SER 17 MODEL 15 OMEGA = 210.45 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
Farr-Jones, S.
Basus, V.J.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
H2 N
16.023
AMINO GROUP
non-polymer
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
UK
J.Mol.Biol.
JMOBAK
0070
0022-2836
248
106
124
10.1006/jmbi.1995.0205
7731037
Solution structure of omega-conotoxin MVIIC, a high affinity ligand of P-type calcium channels, using 1H NMR spectroscopy and complete relaxation matrix analysis.
1995
US
Neuron
NERNET
2038
0896-6273
9
69
A New Conus Peptide Ligand for Mammalian Presynaptic Ca2+ Channels
1992
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
2761.348
OMEGA-CONOTOXIN M VII C (M SEVEN C)
1
nat
polymer
SNX-230
no
yes
CKGKGAPCRKTMYDCCSGSCGRRGKC(NH2)
CKGKGAPCRKTMYDCCSGSCGRRGKCX
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
magus cone
Conus
sample
6492
VENOM DUCT
Conus magus
pdbx_database_status
pdbx_struct_assembly
pdbx_struct_oper_list
struct_conf
struct_conf_type
repository
Initial release
Version format compliance
Version format compliance
Derived calculations
Other
1
0
1995-12-01
1
1
2008-03-24
1
2
2011-07-13
1
3
2017-11-29
_pdbx_database_status.process_site
Y
BNL
1994-12-20
REL
REL
15
PEARLMAN,CASE,CALDWELL,SEIBEL,SINGH,WEINER,KOLLMAN
refinement
AMBER
4.1
CYS
1
n
1
CYS
1
A
LYS
2
n
2
LYS
2
A
GLY
3
n
3
GLY
3
A
LYS
4
n
4
LYS
4
A
GLY
5
n
5
GLY
5
A
ALA
6
n
6
ALA
6
A
PRO
7
n
7
PRO
7
A
CYS
8
n
8
CYS
8
A
ARG
9
n
9
ARG
9
A
LYS
10
n
10
LYS
10
A
THR
11
n
11
THR
11
A
MET
12
n
12
MET
12
A
TYR
13
n
13
TYR
13
A
ASP
14
n
14
ASP
14
A
CYS
15
n
15
CYS
15
A
CYS
16
n
16
CYS
16
A
SER
17
n
17
SER
17
A
GLY
18
n
18
GLY
18
A
SER
19
n
19
SER
19
A
CYS
20
n
20
CYS
20
A
GLY
21
n
21
GLY
21
A
ARG
22
n
22
ARG
22
A
ARG
23
n
23
ARG
23
A
GLY
24
n
24
GLY
24
A
LYS
25
n
25
LYS
25
A
CYS
26
n
26
CYS
26
A
NH2
27
n
27
NH2
27
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
identity operation
0.0000000000
0.0000000000
0.0000000000
1
A
A
LYS
GLY
2
3
148.91
1
A
A
GLY
LYS
3
4
-149.22
1
A
A
LYS
CYS
25
26
-149.36
2
A
A
CYS
LYS
1
2
-149.40
2
A
A
ARG
LYS
9
10
-149.89
2
A
A
CYS
SER
16
17
-149.68
2
A
A
GLY
SER
18
19
-149.94
3
A
A
LYS
GLY
4
5
-149.67
3
A
A
ARG
LYS
9
10
-149.53
3
A
A
MET
TYR
12
13
149.80
3
A
A
CYS
SER
16
17
-149.10
3
A
A
GLY
SER
18
19
-149.26
4
A
A
LYS
GLY
2
3
149.39
4
A
A
GLY
LYS
3
4
-149.83
4
A
A
LYS
CYS
25
26
-149.12
5
A
A
GLY
LYS
3
4
-149.54
5
A
A
ARG
LYS
9
10
-149.87
5
A
A
GLY
SER
18
19
-149.93
5
A
A
LYS
CYS
25
26
-148.83
6
A
A
LYS
GLY
2
3
149.18
7
A
A
CYS
LYS
1
2
-149.53
7
A
A
LYS
GLY
2
3
148.72
7
A
A
GLY
LYS
3
4
-149.40
7
A
A
ARG
LYS
9
10
-149.72
7
A
A
CYS
SER
16
17
-149.67
7
A
A
LYS
CYS
25
26
-148.84
8
A
A
LYS
GLY
2
3
149.60
8
A
A
CYS
SER
16
17
-149.92
9
A
A
ARG
LYS
9
10
-149.69
9
A
A
CYS
SER
16
17
-149.59
10
A
A
CYS
LYS
1
2
-149.79
10
A
A
LYS
GLY
2
3
148.67
10
A
A
GLY
LYS
3
4
-149.70
10
A
A
ARG
LYS
9
10
-149.54
10
A
A
CYS
GLY
20
21
-149.79
10
A
A
LYS
CYS
25
26
-149.65
11
A
A
LYS
GLY
2
3
149.99
11
A
A
SER
GLY
17
18
-149.96
12
A
A
ARG
LYS
9
10
-149.87
12
A
A
LYS
CYS
25
26
-148.68
13
A
A
LYS
GLY
2
3
149.83
13
A
A
GLY
LYS
3
4
-149.61
13
A
A
ARG
LYS
9
10
-149.80
13
A
A
LYS
CYS
25
26
-149.40
14
A
A
ARG
LYS
9
10
-149.48
14
A
A
ASP
CYS
14
15
-149.67
15
A
A
CYS
SER
16
17
-149.55
1
A
ARG
23
0.105
SIDE CHAIN
4
A
ARG
9
0.083
SIDE CHAIN
5
A
ARG
9
0.122
SIDE CHAIN
5
A
TYR
13
0.128
SIDE CHAIN
6
A
TYR
13
0.086
SIDE CHAIN
6
A
ARG
22
0.129
SIDE CHAIN
7
A
ARG
9
0.102
SIDE CHAIN
8
A
TYR
13
0.149
SIDE CHAIN
9
A
TYR
13
0.066
SIDE CHAIN
9
A
ARG
23
0.091
SIDE CHAIN
10
A
TYR
13
0.163
SIDE CHAIN
11
A
ARG
9
0.114
SIDE CHAIN
11
A
TYR
13
0.090
SIDE CHAIN
12
A
ARG
9
0.108
SIDE CHAIN
14
A
ARG
9
0.145
SIDE CHAIN
15
A
TYR
13
0.096
SIDE CHAIN
1
-4.27
0.60
121.00
116.73
A
A
A
CB
CG
CD1
TYR
TYR
TYR
13
13
13
N
2
7.76
1.20
111.50
119.26
A
A
A
CB
CA
C
CYS
CYS
CYS
1
1
1
N
2
-4.13
0.60
121.00
116.87
A
A
A
CB
CG
CD1
TYR
TYR
TYR
13
13
13
N
2
13.45
1.50
110.80
124.25
A
A
A
N
CA
CB
CYS
CYS
CYS
26
26
26
N
3
19.45
2.00
110.40
129.85
A
A
A
CB
CA
C
LYS
LYS
LYS
2
2
2
N
3
6.87
1.10
114.20
121.07
A
A
A
CA
CB
SG
CYS
CYS
CYS
16
16
16
N
3
10.20
1.50
110.80
121.00
A
A
A
N
CA
CB
CYS
CYS
CYS
26
26
26
N
4
-4.25
0.60
121.00
116.75
A
A
A
CB
CG
CD1
TYR
TYR
TYR
13
13
13
N
4
9.50
1.50
110.80
120.30
A
A
A
N
CA
CB
CYS
CYS
CYS
26
26
26
N
5
-4.09
0.60
121.00
116.91
A
A
A
CB
CG
CD1
TYR
TYR
TYR
13
13
13
N
6
8.61
1.20
111.50
120.11
A
A
A
CB
CA
C
CYS
CYS
CYS
1
1
1
N
6
-4.93
0.60
121.00
116.07
A
A
A
CB
CG
CD1
TYR
TYR
TYR
13
13
13
N
6
11.68
1.50
110.80
122.48
A
A
A
N
CA
CB
CYS
CYS
CYS
26
26
26
N
7
7.93
1.20
111.50
119.43
A
A
A
CB
CA
C
CYS
CYS
CYS
1
1
1
N
7
-4.29
0.60
121.00
116.71
A
A
A
CB
CG
CD1
TYR
TYR
TYR
13
13
13
N
7
10.93
1.10
114.20
125.13
A
A
A
CA
CB
SG
CYS
CYS
CYS
26
26
26
N
8
13.16
2.10
122.30
135.46
A
A
A
C
N
CA
LYS
GLY
GLY
4
5
5
Y
8
-3.08
0.50
120.30
117.22
A
A
A
NE
CZ
NH2
ARG
ARG
ARG
9
9
9
N
8
-4.83
0.60
121.00
116.17
A
A
A
CB
CG
CD1
TYR
TYR
TYR
13
13
13
N
8
9.92
1.50
110.80
120.72
A
A
A
N
CA
CB
CYS
CYS
CYS
26
26
26
N
9
-3.03
0.50
120.30
117.27
A
A
A
NE
CZ
NH2
ARG
ARG
ARG
9
9
9
N
9
-4.63
0.60
121.00
116.37
A
A
A
CB
CG
CD1
TYR
TYR
TYR
13
13
13
N
9
12.87
1.50
110.80
123.67
A
A
A
N
CA
CB
CYS
CYS
CYS
26
26
26
N
10
-4.77
0.60
121.00
116.23
A
A
A
CB
CG
CD1
TYR
TYR
TYR
13
13
13
N
10
11.57
1.50
110.80
122.37
A
A
A
N
CA
CB
CYS
CYS
CYS
26
26
26
N
11
12.99
2.10
122.30
135.29
A
A
A
C
N
CA
LYS
GLY
GLY
4
5
5
Y
11
-5.09
0.60
121.00
115.91
A
A
A
CB
CG
CD1
TYR
TYR
TYR
13
13
13
N
11
10.18
1.50
110.80
120.98
A
A
A
N
CA
CB
CYS
CYS
CYS
26
26
26
N
12
-4.45
0.60
121.00
116.55
A
A
A
CB
CG
CD1
TYR
TYR
TYR
13
13
13
N
13
-3.19
0.50
120.30
117.11
A
A
A
NE
CZ
NH2
ARG
ARG
ARG
9
9
9
N
13
-4.30
0.60
121.00
116.70
A
A
A
CB
CG
CD1
TYR
TYR
TYR
13
13
13
N
14
-4.08
0.60
121.00
116.92
A
A
A
CB
CG
CD1
TYR
TYR
TYR
13
13
13
N
14
10.61
1.50
110.80
121.41
A
A
A
N
CA
CB
CYS
CYS
CYS
26
26
26
N
15
-4.96
0.60
121.00
116.04
A
A
A
CB
CG
CD1
TYR
TYR
TYR
13
13
13
N
15
12.05
1.50
110.80
122.85
A
A
A
N
CA
CB
CYS
CYS
CYS
26
26
26
N
1
A
LYS
2
-63.05
-169.69
1
A
ARG
9
-109.72
78.19
1
A
LYS
10
-29.23
-67.73
1
A
SER
17
-125.09
-92.05
1
A
CYS
20
-61.40
75.20
2
A
MET
12
-82.60
43.46
2
A
TYR
13
28.29
81.53
2
A
SER
17
-159.67
-92.70
2
A
CYS
20
-66.77
93.60
2
A
ARG
22
78.86
-50.94
2
A
ARG
23
-62.12
7.06
3
A
PRO
7
-58.04
87.78
3
A
MET
12
-97.76
46.88
3
A
CYS
15
-81.71
36.95
3
A
CYS
16
60.36
-33.30
3
A
SER
17
-148.29
-107.06
3
A
CYS
20
-6.66
84.28
4
A
MET
12
-94.64
47.94
4
A
SER
17
-109.46
-91.52
4
A
CYS
20
-66.28
99.27
4
A
ARG
22
-78.66
21.84
5
A
ARG
9
-118.32
67.35
5
A
SER
17
-123.68
-103.15
5
A
CYS
20
-63.87
90.06
6
A
LYS
2
-160.04
-168.56
6
A
LYS
10
-88.16
42.45
6
A
THR
11
-112.92
-92.37
6
A
MET
12
-76.22
37.66
6
A
ARG
22
-154.93
-64.47
7
A
SER
17
-167.01
-90.04
7
A
SER
19
-126.64
-167.19
7
A
ARG
22
59.87
-106.79
8
A
LYS
4
37.58
115.89
8
A
PRO
7
-52.30
96.73
8
A
ARG
9
-118.00
61.31
8
A
MET
12
-80.10
31.42
8
A
CYS
15
-78.16
21.40
8
A
CYS
16
61.81
-34.62
8
A
SER
17
-125.42
-97.17
8
A
ARG
22
68.81
-43.81
9
A
LYS
10
-40.65
-77.26
9
A
MET
12
-83.28
37.58
9
A
TYR
13
57.13
73.38
9
A
SER
17
-167.72
-90.82
9
A
ARG
22
77.82
-57.73
9
A
ARG
23
-67.40
1.96
10
A
LYS
10
-54.63
-70.33
10
A
MET
12
-89.12
35.64
10
A
TYR
13
28.98
61.47
10
A
SER
17
-153.46
63.26
10
A
CYS
20
-35.33
85.92
11
A
LYS
10
-67.24
19.43
11
A
THR
11
-99.41
-91.68
11
A
MET
12
-75.71
38.99
11
A
CYS
15
-68.69
7.71
11
A
CYS
16
68.89
-41.70
11
A
ARG
22
-123.72
-62.43
12
A
LYS
10
-47.87
-76.74
12
A
MET
12
-85.98
38.04
12
A
TYR
13
57.82
71.11
12
A
SER
17
-117.01
-103.30
12
A
ARG
22
74.02
-34.88
13
A
ARG
9
-115.84
66.19
13
A
MET
12
-79.94
30.73
13
A
SER
17
-118.02
-102.69
13
A
ARG
22
-102.11
-64.62
14
A
LYS
10
-36.79
-77.36
14
A
MET
12
-88.90
40.58
14
A
TYR
13
26.65
65.00
14
A
CYS
16
63.10
-47.76
14
A
SER
17
178.74
154.30
14
A
ARG
22
-149.56
-102.67
14
A
ARG
23
-60.57
12.05
15
A
LYS
10
-77.64
30.13
15
A
THR
11
-109.91
-86.23
15
A
MET
12
-73.09
37.78
15
A
CYS
16
68.27
-32.41
15
A
SER
17
-148.49
-93.92
15
A
ARG
23
-151.72
25.02
refinement
AMBER
OMEGA-CONOTOXIN M VII C (M SEVEN C)
SOLUTION STRUCTURE OF OMEGA-CONOTOXIN MVIIC, A HIGH AFFINITY OF P-TYPE CALCIUM CHANNELS, USING 1H NMR SPECTROSCOPY AND COMPLETE RELAXATION MATRIX ANALYSIS
1
Y
N
A
LYS
10
A
LYS
10
HELX_P
A
MET
12
A
MET
12
5
1
3
disulf
2.090
A
CYS
1
A
SG
CYS
1
1_555
A
CYS
16
A
SG
CYS
16
1_555
disulf
2.069
A
CYS
8
A
SG
CYS
8
1_555
A
CYS
20
A
SG
CYS
20
1_555
disulf
2.083
A
CYS
15
A
SG
CYS
15
1_555
A
CYS
26
A
SG
CYS
26
1_555
covale
1.326
A
CYS
26
A
C
CYS
26
1_555
A
NH2
27
A
N
NH2
27
1_555
NEUROTOXIN
P-TYPE CALCIUM CHANNEL BLOCKER, CONUS VENOM, PRESYNAPTIC NEUROTOXIN, CONOTOXIN, NEUROTOXIN
CXO7C_CONMA
UNP
1
1
P37300
TRCKGKGAPCRKTMYDCCSGSCGRRGKCG
3
28
1OMN
1
26
P37300
A
1
1
26
3
anti-parallel
anti-parallel
A
ALA
6
A
ALA
6
A
CYS
8
A
CYS
8
A
GLY
24
A
GLY
24
A
CYS
26
A
CYS
26
A
SER
19
A
SER
19
A
GLY
21
A
GLY
21
BINDING SITE FOR RESIDUE NH2 A 27
Software
4
A
CYS
15
A
CYS
15
4
1_555
A
SER
19
A
SER
19
4
1_555
A
LYS
25
A
LYS
25
4
1_555
A
CYS
26
A
CYS
26
4
1_555
1
P 1